Velcade® Patent Validated by CAFC

August 8, 2017

Millennium Pharmaceuticals, Inc. v. Sandoz Inc. (Fed. Cir. 2017)

A Court of Appeals for the Federal Circuit (CAFC) panel reversed the district court’s holding that Millennium’s licensed patent, U.S. Patent No. 6,713,446 (“the ‘446 Patent”) was invalid for being obvious. The ‘446 Patent claimed a lyophilized mannitol ester prodrug of Bortezomib (See Claim 20). Claim 20 was not obvious according to the panel because, among other reasons, the inventors unexpectedly “discovered that the reason for the dramatic improvement in dissolution and stability for this formulation was the formation of a new chemical compound during lyophilization: the claimed ester of bortezomib and mannitol.”

  • Claim 20:  The lyophilized compound D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.

Earlier, the district court concluded that the new compound was obvious reasoning that Bortezomib was already known (U.S. Patent No. 5,780,454), Lyophilization is already known known, and that the claimed compound is “the inherent result of an allegedly obvious process” of  lyophilizing bortezomib and mannitol together.

  • There was no evidence that anyone “foresaw, or expected, or would have intended, the reaction between bortezomib and mannitol, or that the resulting ester would have the long-sought properties and advantages”
  • “The district court did not find that the prior art taught or suggested that the claimed new compound would be formed, or taught or suggested making the claimed new compound by any method, or taught or suggested that this new compound would have the properties of stability, solubility, and dissociability that it exhibited.”
  • “No reference taught or suggested reacting bortezomib with mannitol, and no reference hinted that such an esterification reaction might occur during lyophilization.”
  • “No reference taught or suggested that the product of such lyophilization would be a new chemical compound that would solve the problems that had inhibited development of bortezomib in oncology.”
IP Watchdog Post by Jay Pattumudi:
http://www.ipwatchdog.com/2017/08/10/inherent-obviousness-motivation-modify-lead-compound-surprising-unexpected-results/id=86661/
Patent Docs Post:
http://www.patentdocs.org/2017/07/millennium-pharmaceuticals-inc-v-sandoz-inc-fed-cir-2017.html
Dilworth IP Post:
http://www.dilworthip.com/nonobviousness-push-back-millennium-pharma-v-sandoz/
VELCADE® Prescribing Information:
http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf
VELCADE® (bortezomib) Official Website:
http://www.velcade.com/

SCOTUS Opinion on Patent Exhaustion

June 2, 2017

The Supreme Court Tuesday issued its decision on patent exhaustion on Tuesday May 30, 2017. (Impression Products, Inc. v. Lexmark International, Inc.)

Below are a few blog posts for reading.

Supreme Court Holds Patent Exhaustion is Not Limited to U.S. Sales

Supreme Court Holds that Any Sale of a Patented Product Exhausts Patent Holder’s Rights

U.S. Supreme Court Significantly Restricts Patent Owners’ Ability to Control Resale of Patented Items

 

Carbon Black

For the Interesting Patents file:

C&EN recently published an interesting article on Orion Engineered Carbons GbmH and its strategy of making and selling the most sophisticated grades of carbon black it can.

Carbon Black is a is a material produced by the incomplete combustion of heavy petroleum products. It is widely used as reinforcing filler material for rubber.   [Tires, tire treads, cable sheathing, hoses, drive belts, conveyor belts, roll coverings, shoe soles, sealing rings, profiles, and damping elements.]  Carbon black is also used as a pigment. That’s not surprising given its name.

A recent carbon black patent issued to Orion is US 8,735,488.

US 8,735,488

Claim 1.  A carbon black, characterized in that the CTAB surface area is from 100 to 160 m2/g, the quartile ratio is greater than 1.60, and the FP index is >0.

Recent Doctrine of Equivalence Case: “Insubstantial Differences” Test May Be More Suitable than a “Function-Way-Result” Test for Chemical Arts.

The Doctrine of Equivalence is alive and well.  For the chemical arts, the CAFC recently suggested that the “Insubstantial Differences” test may be more suitable than a “Function-Way-Result” Test.

See Christopher E. Loh’s post for Fitzpatrick, Cella, Harper & Scinto

 

When is and “and?” When is and “or?”

May 12, 2017  –  [Looking back to 2008 case]

“And” Connotes Alternatives in Topiramate Litigation

When is and “and?” When is and “or?” That sounds silly. But reading Chisum on Patents in the law library reminded me of one of the holdings in the topiramate litigation of Ortho-McNeil v. Mylan, 520 F.3d 1358 (Fed. Cir. 2008), in which the meaning of and was taken seriously. While most dictionary definitions of “and” are additive, dictionary definitions also show use of “and” to “connote alternatives.”

In the Ortho-McNeil v. Mylan case, the Court of Appeals of the Federal Circuit (CAFC) held that the term “and,” in Ortho-McNeil’s claim [US Pat. No. 4,513,006 “Anticonvulsant Sulfamate Derivatives”] was used to connote alternatives rather than in the additive sense.

Ortho-McNeil’s US Pat. No. 4,513,006 claimed a genus of sulfamates covering Topiramate. The disputed clause stated: “R2, R3, R4, and R5 are independently hydrogen or lower alkyl and R2 and R3 and/or R4 and R5 together may be a group of formula (II).” (Emphasis added) [A full copy of claim 1 appears below.]

The CAFC said that the two subsets did not need to simultaneously exist. The claim was not limited to compounds that were in both subsets because, construed in context, the claim to compounds that were of a first subset “and” a second subset covered compounds that were either in the first group “or” the second subset.

Here “and” meant to “join alternatives” because, in this case, the claim did not use the word “and” in isolation. Rather, the claim used “and” in a larger context with clarifying adverbs “independently” and “together.”

More on the word “AND”

Chef America v. lamb-Weston, 358 F.3d 1371 (Fed. Cir. 2004)

  • A court may not re-write a patent claim even to avoid a nonsensical result.
  • Here, however, giving “and” its most common dictionary meaning would fail to cover the patent owners own drug product and render dependent claims meaningless

The CAFC distinguished Chef America:

To the contrary, this court and the district court must interpret the term to give proper meaning to the claim in light of the language and intrinsic evidence. Giving and its most common dictionary meaning would produce in this case the nonsensical result of not covering topiramate and rendering several other dependent claims meaningless. In Chef America, the only possible interpretation of the claim led to a nonsensical result. This situation is distinguishable because claim 1 can and should be interpreted as the patentees intended, with the meaning of and connoting alternatives.

https://en.wikipedia.org/wiki/Topiramate

Topiramate claim 1-1

4-Aminopyridine: Acorda Win & Loss

May 3, 2017

Acorda won at the PTAB but lost in the US District Court.

Acorda Therapeutics, Inc. is fighting is to extend the life of their 4-aminopyridine formulations and methods.

Acorda will retain market exclusivity to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg at least through July 2018.

The US District Court in Delaware ruled that Acorda’s four patents set to expire between 2025 and 2027 are invalid.  A few weeks earlier, the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld the four patents challenged via the inter partes review (IPR) process [U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,440,703 (the ‘703 patent), 8,354,437 (the ‘437 patent) and 8,007,826 (the ‘826 patent)]. These patents, if valid and enforceable, are calculated to expire in 2025, 2025, 2026 and 2027, respectively.

ACORDA THERAPEUTICS, INC., et al. v. ROXANE LABORATORIES, INC., et al.

Case #: 14-882
Judge: Chief Judge Leonard P. Stark

Next?: Acorda will appeal. Meanwhile Acorda announced restructuring and layoffs

http://www.4-traders.com/ACORDA-THERAPEUTICS-INC-8238/news/Acorda-Therapeutics-Implements-Corporate-Restructuring-to-Align-Cost-Structure-with-Focus-on-Promi-24209186/

http://cen.acs.org/articles/95/i15/Troubled-biotechs-cut-jobs.html

Fierce Pharma

http://www.fiercepharma.com/pharma/court-nixes-4-acorda-patents-teeing-up-amprya-generics-for-2018

Acorda press releases

03/31/2017: http://ir.acorda.com/investors/investor-news/investor-news-details/2017/US-District-Court-Issues-Decision-to-Invalidate-Four-AMPYRA-Patents-Company-Will-Appeal-Ruling/default.aspx

03/09/2017: http://ir.acorda.com/investors/investor-news/investor-news-details/2017/Patent-Trials-and-Appeal-Board-PTAB-Upholds-Four-AMPYRA-Patents/default.aspx

Nucleophilic Covalent Drugs

May 1, 2017

Prof. Kate Carroll of Scripps Research Institute extended covalent drug discovery to cysteine-oxidized proteins by developing a library of nucleophilic drug candidates. For example, Prof. Carroll provided pyrolidinedione nucleophiles that react with protein tyrosine phosphatases.

See J.AmChem.Soc. 2017, DOI:10.1021/jacs.7b01791

http://pubs.acs.org/doi/10.1021/cen-09517-notw7

US 2016/0195532 “Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines”

 

 

Exit mobile version